Profile: The Spectranetics Corporation manufactures and markets the excimer laser system for use in minimally invasive interventional procedures within the cardiovascular system. The spectranetics laser system utilizes a wavelength of 308 nanometers in the ultraviolet region of the light spectrum. The laser dissolves arterial plaque without harming the healthy tissues. The excimer laser ablation vaporizes the obstruction in a safer, simpler fashion than other modalities. Our product categories include vascular intervention, excimer laser system, peripheral vascular, coronary vascular, lead management, excimer laser sheath and lead locking devices. We provide CVX-300 xenon chloride gas excimer laser units, laser sheath for use in conjunction with the CVX-300 to assist in removing pacer or ICD leads by ablating scar tissues, laser-assisted pacemaker lead removal devices and laser sheath designed to thread over an implanted pacing lead & ablate through scar tissues, thereby aiding in the extraction of the pacing lead. Our vascular intervention (VI) products include a range of peripheral & cardiac laser catheters for ablation of occluded arteries in the legs, both above and below the knees & within the coronary arteries. We also market aspiration catheters for the removal of thrombus and support catheters to facilitate crossing of coronary & peripheral arterial blockages. Our turbo elite laser ablation catheter is indicated for use in the treatment of infrainguinal stenoses and occlusions.

The company was founded in 1984, has revenues of USD 50-100 Million, has ~310 employees and is ISO 9000, ISO 9001, CE certified. NASDAQ:SPNC (SEC Filings)